A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Key Inclusion Criteria:

1. The participant has a body mass index (BMI) within the range of 18.5 to 50 kg/m^2,inclusive.

2. The participant has diagnosed or suspected moderate or severe obstructive sleepapnea (OSA) based on one of the criteria below: a. The participant has a snoring, tiredness, observed apnea, high blood pressure,body mass index, age, neck circumference, and gender questionnaire (STOP-Bang) score ≥5 at the screening visit. OR b. The participant has a diagnosis of moderate orsevere OSA based on an in-clinic polysomnography (PSG) or home sleep test with anapnea-hypopnea index (AHI) or respiratory event index (REI) score of ≥15 and theyhave not had significant weight loss since their diagnostic test, in the judgment ofthe investigator.

3. The participant is scheduled for major abdominal surgery invading theintraperitoneal or retroperitoneal space (open or laparoscopic) that will require atleast 1 inpatient overnight stay.

4. The participant is scheduled to undergo a surgery requiring general anesthesia andendotracheal intubation.

5. The participant's surgery, as planned, is anticipated to require use of IV opioidsin the postanesthesia care unit (PACU).

6. The duration of the participant's surgery (i.e., incision to last stitch) isexpected to be at least 2 hours and up to approximately 8 hours.

7. The participant has an American Society of Anesthesiologists (ASA) Classification ofII to III.

Key Exclusion Criteria:

1. The participant has an AHI or REI score <15 based on in-clinic PSG test or at-homesleep test within 2 years before screening.

2. The participant is undergoing liver or kidney surgery.

3. The participant has a planned transfer to the intensive care unit (ICU) from theoperating room.

4. For the participant, immediate (continuous positive airway pressure [CPAP]/ bilevelpositive airway pressure [BiPAP]) use in the PACU is anticipated or planned.

5. The participant has undergone major surgery or donated or lost ≥1 unit of blood (approximately 500 mL) within 4 weeks before the screening visit.

6. The participant has received chemotherapy or radiation therapy within 4 weeks beforeadministration of the study drug.

7. The participant has poorly controlled diabetes with an episode of ketoacidosiswithin 6 months of the screening visit.

8. The participant has a positive test result for hepatitis B surface antigen,hepatitis C virus (HCV), human immunodeficiency virus antibody/antigen at screening.

9. The participant has uncontrolled hypertension or unstable cardiovascular disease (presence of acute coronary syndrome, unstable angina, myocardial infarction <3months, severe valvular disease, or severe structural heart disease), severe heartfailure, or any condition requiring a pacemaker or defibrillator.

10. The participant has a screening electrocardiogram (ECG) with a QT interval withFridericia correction method (QTcF) >450 milliseconds [ms] (for men) or >470 ms (forwomen).